Eli Lilly and Company $LLY Shares Sold by Galvin Gaustad & Stein LLC

Key Points

• Galvin Gaustad & Stein LLC reduced its holdings in Eli Lilly by 19.8%, selling 311 shares during the second quarter, bringing its total ownership to 1,263 shares valued at approximately $984,000.
• Eli Lilly's stock saw a 2.6% decline, with shares trading at $833.08; the company reported a significant increase in quarterly earnings of $6.31 per share, surpassing estimates.
• Institutional investors currently own 82.53% of Eli Lilly's stock, indicating strong institutional interest and support for the company's shares.

Galvin Gaustad & Stein LLC decreased its holdings in shares of Eli Lilly and Company (NYSE:LLY - Free Report) by 19.8% in the 2nd quarter, according to its most recent Form 13F filing with the SEC. The firm owned 1,263 shares of the company's stock after selling 311 shares during the period. Galvin Gaustad & Stein LLC's holdings in Eli Lilly and Company were worth $984,000 at the end of the most recent quarter.

Other hedge funds have also made changes to their positions in the company. WestEnd Advisors LLC boosted its stake in shares of Eli Lilly and Company by 210.0% during the first quarter. WestEnd Advisors LLC now owns 31 shares of the company's stock worth $26,000 after buying an additional 21 shares during the period. Wealth Preservation Advisors LLC acquired a new stake in Eli Lilly and Company in the first quarter valued at about $27,000. Citizens National Bank Trust Department lifted its position in Eli Lilly and Company by 180.0% in the first quarter. Citizens National Bank Trust Department now owns 42 shares of the company's stock valued at $35,000 after purchasing an additional 27 shares during the period. Financial Gravity Asset Management Inc. acquired a new stake in Eli Lilly and Company in the first quarter valued at about $40,000. Finally, TD Capital Management LLC lifted its position in Eli Lilly and Company by 129.2% in the first quarter. TD Capital Management LLC now owns 55 shares of the company's stock valued at $46,000 after purchasing an additional 31 shares during the period. Institutional investors and hedge funds own 82.53% of the company's stock.

Eli Lilly and Company Trading Down 2.6%

Shares of Eli Lilly and Company stock opened at $833.08 on Friday. Eli Lilly and Company has a 12-month low of $623.78 and a 12-month high of $937.00. The company has a current ratio of 1.28, a quick ratio of 1.00 and a debt-to-equity ratio of 1.86. The stock has a market cap of $788.47 billion, a PE ratio of 54.45, a price-to-earnings-growth ratio of 1.19 and a beta of 0.47. The company has a 50-day moving average of $742.42 and a two-hundred day moving average of $766.36.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last issued its earnings results on Thursday, August 7th. The company reported $6.31 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $5.59 by $0.72. Eli Lilly and Company had a net margin of 25.91% and a return on equity of 92.72%. The company had revenue of $15.56 billion during the quarter, compared to analysts' expectations of $14.40 billion. During the same period last year, the company posted $3.92 earnings per share. The firm's quarterly revenue was up 37.6% compared to the same quarter last year. Eli Lilly and Company has set its FY 2025 guidance at 21.750-23.000 EPS. On average, research analysts anticipate that Eli Lilly and Company will post 23.48 EPS for the current fiscal year.

Insider Buying and Selling at Eli Lilly and Company

In other Eli Lilly and Company news, Director Gabrielle Sulzberger acquired 117 shares of the company's stock in a transaction dated Tuesday, August 12th. The stock was acquired at an average cost of $641.18 per share, with a total value of $75,018.06. Following the purchase, the director directly owned 2,703 shares in the company, valued at approximately $1,733,109.54. This trade represents a 4.52% increase in their position. The acquisition was disclosed in a filing with the SEC, which is available through this link. Also, Director J Erik Fyrwald acquired 1,565 shares of the company's stock in a transaction dated Tuesday, August 12th. The shares were acquired at an average cost of $642.33 per share, with a total value of $1,005,246.45. Following the completion of the purchase, the director owned 74,578 shares in the company, valued at approximately $47,903,686.74. This represents a 2.14% increase in their ownership of the stock. The disclosure for this purchase can be found here. Over the last 90 days, insiders bought 4,514 shares of company stock worth $2,894,841. 0.13% of the stock is currently owned by insiders.

Analyst Ratings Changes

A number of equities research analysts recently commented on LLY shares. JPMorgan Chase & Co. reduced their price objective on shares of Eli Lilly and Company from $1,100.00 to $1,050.00 and set an "overweight" rating for the company in a research report on Tuesday, September 16th. Hsbc Global Res upgraded shares of Eli Lilly and Company from a "moderate sell" rating to a "hold" rating in a research report on Wednesday, August 27th. Wall Street Zen downgraded shares of Eli Lilly and Company from a "strong-buy" rating to a "buy" rating in a research report on Saturday, September 20th. UBS Group reduced their price objective on shares of Eli Lilly and Company from $1,050.00 to $895.00 and set a "buy" rating for the company in a research report on Friday, August 8th. Finally, Leerink Partners restated a "market perform" rating and issued a $715.00 price objective on shares of Eli Lilly and Company in a research report on Thursday, August 7th. One analyst has rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating and ten have given a Hold rating to the company's stock. According to MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and a consensus target price of $948.56.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.